Drug interactions between daptomycin and Lipitor
Results for the following 2 drugs: |
|
|---|---|
| daptomycin | |
| Lipitor (atorvastatin) | |
Interactions between your selected drugs
atorvastatin ⇔ daptomycin
Applies to: Lipitor (atorvastatin) and daptomycin
GENERALLY AVOID: There is some theoretical concern regarding the potential for additive musculoskeletal toxicity during coadministration of daptomycin and HMG-CoA reductase inhibitors. In animals, daptomycin has been associated with skeletal muscle effects characterized by degenerative/regenerative changes and variable elevations in creatine phosphokinase (CPK). Elevations in serum CPK were also reported more frequently in daptomycin-treated patients than in comparator-treated patients (2.8% vs. 1.8%) in phase 3 clinical trials. Similarly, HMG-CoA reductase inhibitors are known to occasionally cause myopathy manifested as muscle pain and/or weakness in association with grossly elevated levels of CPK. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. There were no reports of skeletal myopathy in a placebo-controlled Phase 1 trial in which 10 healthy subjects on stable simvastatin therapy (40 mg/day) were treated concurrently with daptomycin (4 mg/kg IV once every 24 hours) for 14 days. In addition, they did not have a higher incidence of adverse effects compared to 10 patients in the placebo group. Myopathy has not been reported in clinical trials of daptomycin.
MANAGEMENT: Due to the limited nature of existing data, consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving daptomycin. All patients receiving daptomycin should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. CPK levels should be monitored weekly, and patients who develop unexplained elevations in CPK should be monitored more frequently. Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK levels exceeding 1000 U/L (approximately 5 times the upper limit of normal), or in patients without reported symptoms who have marked elevations in CPK (10 times the upper limit of normal, or more).
See also...
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
